本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ON JANUARY 26, 2024, AT 11:20 FINNISH TIME / 10:20 SWEDISH TIME. HELSINKI, Jan. 26, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that one of its leading nanoformulation drug products had received promising clinical results. These were from a relative bioavailability study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation, an alternative to the amorphous solid dispersion (ASD) used in Xtandi®[1], the number one prescribed androgen receptor inhibitor[2] first approved by the FDA in 2012, and by the EMA in 2013 to treat prostate cancer. The nanoenzalutamide tablet formulation was developed in a partnership with the ONConcept® Consortium (Bluepharma, Helm, and Welding) whereby Nanoform's proprietary controlled expansion of supercritical solutions (CESS®) technology provides the opportunity for an improved and differentiated finished product. Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a 160mg, single tablet per day regimen may be preferable for patients in need of reducing their total number of daily pills. The single-dose, randomized, comparative bioavailability study, which was performed by a contract research organization (CRO) in North America and completed on January 25, 2024, compared enzalutamide 160mg filmcoated tablets (Bluepharma) and Xtandi® 4x40 mg film-coated tablets (Astellas Pharma Europe B.V.). The clinical trial demonstrated promising results. Nanoform and ONConcept® will further analyze these results prior to moving ahead to enter the phase of process validation and pivotal clinical trials. A patent application for the nanoenzalutamide formulation has already been jointly filed by Helm and Nanoform. We aim for the product launch after the expiry of the enzalutamide substance patent in the respective territories. For the United States this patent expiry is expected in 2027, and in Europe in 2028. This unique IP position may allow the nanoenzalutamide product to enter the market prior to other generic competition based on the ASD formulation, which is currently patent protected in the US and Europe until 2033. "We are delighted to have achieved promising results from this clinical trial, bringing closer the prospect of making the lives of prostate cancer patients around the world easier in their daily struggle managing this common disease", said Dr. Edward Haeggström, Chief Executive Officer of Nanoform. "This program exemplifies the opportunity available to create novel and improved dosage forms of existing medicines and to ensure that those drugs in clinical development are patient-centric before they reach the market. Together with our ONConcept® Consortium partners, we look forward to executing licensing deals this year and in the future to commercialize nanoenzalutamide." [1] Xtandi is a registered trademark of Astellas Pharma Inc. [2] Source: xtandi.com Nanoform will present the conclusions in a live webcast presentation and conference call on Friday January 26, 2024, at 14:00 Helsinki time / 13:00 Stockholm time. Following the presentation there will be a question-and-answer session. Please note that you must dial in to present questions. The presentation will be broadcast live as a webcast available at: https://ir.financialhearings.com/pressconf-january-2024 Teleconference dial-in numbers: Register using the link below to receive dial-in details and a conference ID for the webinar and conference call. https://conference.financialhearings.com/teleconference/?id=5001857 For further information, please contact: Christian Jones, Chief Commercial OfficerChristian.jones@nanoform.com+44 7804 474 771 For investor relations queries, please contact: Henri von Haartman, Director of Investor Relationshvh@nanoform.com+46 7686 650 11 About Nanoform Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com. About ONConcept® Consortium The three independent and certified European pharmaceutical companies - Bluepharma, Helm and Welding - joined forces in 2019 after identifying a significant opportunity for a leading partnership that can develop and manufacture complex, differentiated and highly potent products for licensing to pharmaceutical companies operating in markets around the world. ONConcept® consortium develops a portfolio of more than 15 molecules and makes them available for licensing and distribution by pharmaceutical companies around the world. The consortium is based on a profound international network and global experience in value-added products, in-house scientific-, IP-, regulatory-, and commercial expertise to be in the position to offer services covering the entire value chain according to customer needs. Bluepharma (Portugal) operates as a contract development and manufacturing organization and has in-house all the capabilities needed to develop a medicine from scratch and, in the period before the formation of ONConcept®, began applying them to the development of complex products. Bluepharma has global regulatory approvals and experience filing submissions with authorities around the world. Helm AG (Germany) has a strong track record of collaborating with international partners to apply its scientific, IP, regulatory and quality expertise to the development of generic and differentiated pharmaceuticals. The work has turned Helm into an experienced coordinator of different stakeholders and an expert in handling active pharmaceutical ingredients. WELDING (Germany) has built an excellent reputation for leading projects from start to finish. Since its establishment in 1955, WELDING has been serving as a trusted global partner to companies worldwide. We distribute raw materials and offer a wide range of ready-to-use drug formulations to the healthcare community. Nanoform Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2022 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The following files are available for download: https://mb.cision.com/Main/18905/3916282/2564958.pdf Release
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi®[1], the number one prescribed androgen receptor inhibitor[2] first approved by the FDA in 2012 to treat prostate cancer. The single-dose, randomized, comparative bioavailability study, which is performed by a contract research organization (CRO) in North America, compares enzalutamide 160 mg film-coated tablets (Bluepharma Farmaceutica S.A.) and Xtandi 4x40 mg film-coated tablets (Astellas Pharma Europe B.V.). Clinical trial read-out is expected during Q1 2024. Tablet-burden and dysphagia are well-documented challenges for prostate cancer patients, and the development of a 160mg, single tablet per day regimen enabled by Nanoform technology and formulation expertise may be preferable for patients in need of reducing their total number of daily pills. "We are pleased to have achieved First Subject First Visit as planned. The initiation of this trial represents a key milestone as we advance the development of nanoenzalutamide in prostate cancer for patients," said Dr. Edward Haeggström, Chief Executive Officer of Nanoform. "We continue our discussions with specialty pharma and value-added medicine partners to ensure this advance reaches the patients that need it the most. We see significant interest in nanocrystalline alternatives for Amorphous Solid Dispersions from pharma and value-added medicine partners, for whom this platform technology offers a differentiated and improved formulation that could reduce pill burden, provide a preferred route of administration or improve patient experience, acceptance and adherence." If the results are positive, Nanoform and its partners will seek one or more license and/or commercial supply agreements during 2024 and equally retain 25% share of the net-income. Nanoform and three other parties have equally funded this development program. The nanoformed enzalutamide API was manufactured at Nanoform's state-of-the-art GMP manufacturing facility in Helsinki using its proprietary ccontrolled expansion of supercritical solutions (CESS®) technology, designed to improve bioavailability, reduce the need for polymers or excipients, improve dose loading, and provide a superior patient experience. [1] Xtandi is a registered trademark of Astellas Pharma Inc. [2] Source: xtandi.com For further information, please contact: Christian Jones, Chief Commercial Officer Christian.jones@nanoform.com +44 7804 474 77 41 For investor relations queries, please contact: Henri von Haartman, Director of Investor Relations hvh@nanoform.com +46 7686 650 11 For media queries, please contact: Chris Halling, Director, Orientation Marketing Ltd. +44 (0)7580 041 073 chris.halling@orientation.agency About Nanoform Nanoform is a medicine performance enhancing company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2022 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The following files are available for download: https://mb.cision.com/Main/18905/3904440/2523558.pdf Release
ZURICH, March 22, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR) (ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced a joint research project agreement with Nfinite Nanotechnology Inc. to validate the use of Nfinite's nanocoating technology to enhance both recyclable and compostable packaging. In the proof-of-concept phase of the project, Nfinite's coating technology will be applied to Amcor's existing recyclable and compostable packaging material. The objective is to deliver an oxygen barrier to improve performance for recyclable and compostable packaging. Once validated, the next stage of development will seek to ensure the products are optimized to Amcor's manufacturing processes and analyze additional substrates like bio-based materials to create more sustainable applications. This project marks an important milestone in the partnership between Amcor and Nfinite that began in 2022 when Nfinite was selected as an Amcor Lift-Off winner. In addition to receiving $250,000 in seed funding, Amcor Lift-Off start-ups have the opportunity to work with Amcor's Research & Development team to create new applications that can advance both companies' efforts toward driving circularity. Amcor Vice President of Corporate Venturing and Open Innovation, Frank Lehmann, said, "This joint research project agreement is an important step, and showcases Amcor's solution-based commitment to sustainability and innovation. Collaborating with innovative start-ups like Nfinite, particularly in the early stage of this exciting new technology, is one more way we are working to advance our shared sustainability goals." Chee Hau Teoh, co-founder and CEO at Nfinite Nanotechnology, said, "We're very pleased to have Amcor's support in advancing our ambitions to deliver this nanocoating technology in packaging applications. Once scaled up, we can begin looking for pilot companies eager to leverage this technology." To learn more about how Amcor's collaboration with Nfinite began as a result of the Corporate Venturing team's Amcor Lift-Off program, click here. About Amcor Amcor is a global leader in developing and producing responsible packaging solutions for food, beverage, pharmaceutical, medical, home and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve supply chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company is focused on making packaging that is increasingly lighter weight, recyclable and reusable, and made using an increasing amount of recycled content. In fiscal year 2022, 44,000 Amcor people generated $15 billion in annual sales from operations that span 220 locations in 43 countries. NYSE: AMCR; ASX: AMCwww.amcor.com I LinkedIn I Facebook I YouTube About Nfinite Nanotechnology Nfinite Nanotechnology is a venture-backed advanced material company based in Waterloo, Canada, that aims to build a more sustainable world through the advancement of compostable and recyclable packaging. Nfinite's breakthrough nanocoating technology is based on more than 10 years of science and experience in the development of advanced functional thin films. Nfinite is commercializing its rapid, open-air nanocoating platform, which produces large-area, high-quality, ultrathin-films at low cost. Nfinite's mission is to provide the packaging industry with a sustainable path forward by delivering high-performance barriers layers for sustainable packaging, accelerating the world's goal to eliminate plastic packaging pollution.
新罕布什爾斯旺茲, Oct. 04, 2022 (GLOBE NEWSWIRE) -- 全球領先的超精密加工系統供應商 Moore Nanotechnology Systems（「Nanotech」）宣佈在北卡羅來納州夏洛特開設其全球培訓與流程開發中心。 Nanotech 主席兼行政總裁 Mark Boomgarden 分享道：「Nanotech 非常高興宣佈我們在北卡羅來納州夏洛特開設我們的全球培訓和流程開發中心的盛大開業。儘管該設施最初的重點是提供特定的客戶培訓和行業領先的流程開發，但亦提供 Nanotech 增量生產能力，以滿足快速增長的市場需求。」 Nanotech 購買並最近完成了位於北卡羅來納夏洛特州 Northpark Corporate Park 的一棟 50,000 呎建築的裝修。 Nanotech 的核心技術與和員工基礎位於新罕布什爾州斯旺茲，而這個是建基於他們提供的產品和服務的基礎。但隨著該組織不斷發展，Nanotech 需要找到一個生態系統來幫助扶植和加速增長，而夏洛特地區允許 Nanotech 進入世界一流的大學、國際機場及一個具有基礎設施以支援全球業務的城市。 北卡羅來納大學夏洛特分校工程院長 Robert Keynton 補充說：「 Nanotech 在夏洛特擴大設施的優勢之一，它加強我們的合作與關係，包括聘用我們的學生。」 Keynton 繼續說：「但它也讓他們能夠存取我們的教師正在進行的尖端研究，並將這些知識整合到他們的系統。」 隨著光學系統的需求變得越來越複雜並從真實應用發展到虛擬應用，Nanotech 持續看到顯著的增長。支援這些系統製造所需的知識和流程開發亦大幅增加。 Nanotech 銷售與服務副總裁 Scott Gerhart 評論道：「培訓和應用程式支援是我們產品和服務的根本，而在當今的市場中，這亦是我們客戶的期望。」 Gerhart 繼續說：「正因如此，我們的業務取決於聘用超精密加工領域的頂尖人才。這些學生將從夏洛特北卡羅來納大學的精密製造和測量計劃中脫穎而出，為我們在 Nanotech 中取得成功所需的角色作出非常充分的準備。」 工程副總裁 Paul Vermette 表示：「隨著我們的客戶不斷提升其內部能力，以滿足行業嚴苛的產品要求，Nanotech 持續領先於曲線第 1 至第 2 代。」 Vermette 繼續說：「我們的 5 年產品和技術路線圖是根據客戶意見所建立，與我們的內部投資結合時，為 Nanotech 提供實現這些目標所需的策略方向。」 這家新的 Nanotech 設施位於夏洛特的 6510 Northpark Blvd，距住宅區和夏洛特道格拉斯國際機場 15 分鐘路程。該設施於 2022 年進行翻新，包括在 24 吋混凝土隔離墊上擴建 10,000 級潔淨室，並且溫度控制在攝氏 +/- 0.1 度。此外，該設施已升級為包括溫度控制的高棚製造空間，以及支援客戶參與的最先進培訓中心。 Moore Nanotechnology Systems (Nanotech) 於 1997 年在新罕布什爾州基恩成立，是 Moore Tool Company 的獨立子公司。在 2010 年，公司搬遷至新罕布什爾州斯旺茲的一個現代化的專用設施，並於 2020 年在北卡羅來納州康科德開設了一家廠房。超過 25 年，Nanotech 在設計、開發和製造最先進超精密機床以及相關技術（單點金剛石切削、微銑削、微研磨和玻璃壓模）方面是全球領導者，為消費電子、太空、國防、航空、照明、醫療及汽車範疇的先進光學組件。Moore Tool 成立於 1924 年，位於康涅狄格州的布里奇波特，在精密和超精密機床市場上擁有悠久的歷史。至今，Moore Tool 提供了完整的高性能 CNC 夾具磨床系列，以及通過 ISO 9001:2015 和 AS9100D 認證的合約精密製造服務。Moore Nanotechnology Systems 與 Moore Tool 已垂直整合到 PMT Group 旗下。 Moore Nanotechnology Systems 網址：www.nanotechsys.com Moore Tool, Inc 網址：www.mooretool.com 如欲了解更多資訊，請聯絡：sales@nanotechsys.com
SHENZHEN, China, Jan. 11, 2025 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), today announced the research on holographic technology based on quantum tensor network states. Quantum tensor network states are a class of states that can effectively compress quantum data, making it possible to simulate large-scale quantum systems with limited quantum bit resources. (1) Selection and Preparation of Quantum Bits HOLO first carefully selects high-quality quantum bits and employs advanced ion trapping technology to construct a stable and reliable quantum bit system within the quantum processor. Ion trapping technology offers excellent quantum state control and low noise levels, effectively enhancing the performance of quantum bits. For example, when preparing the initial state of the quantum bits, HOLO uses precise laser control to trap ions in specific potential wells and initializes their quantum states to the desired configurations. They adjust the ions' internal energy levels using the frequency and intensity of the laser, ensuring that the ions are in an optimal state for quantum computation. At the same time, through precise electromagnetic field control, they regulate the interactions between multiple ions, laying the foundation for building quantum tensor networks. (2) Constructing the Quantum Tensor Network Constructing the quantum tensor network is one of the core steps of HOLO's holographic technology. Through in-depth research into the mathematical structure and physical properties of quantum tensor networks, a series of efficient algorithms and tools have been developed for constructing and optimizing quantum tensor networks within the quantum processor. First, the state of the quantum system is represented as a tensor network structure, where each tensor represents the state of a quantum bit or a group of quantum bits. By adjusting the connections and parameters between the tensors, effective compression and representation of the quantum system are achieved. For example, in the process of simulating the evolution of an infinitely long entangled initial state, HOLO utilizes the properties of quantum entanglement to represent the entanglement relationships between multiple quantum bits as the connecting edges within the tensor network. By precisely controlling the strength and direction of these connecting edges, the simulation and evolution of quantum entangled states are realized. (3) Simulating the Dynamics of Infinite Entangled States After constructing the quantum tensor network, HOLO began simulating the dynamics of infinite entangled states. Leveraging the powerful computational capabilities of the quantum processor, they performed dynamic evolution calculations on the quantum tensor network. By precisely controlling the operations and interactions of the quantum bits, HOLO was able to simulate and track the evolution process of infinite entangled states. In this process, HOLO employed advanced quantum algorithms and optimization techniques to enhance the efficiency and accuracy of the computations. For instance, they utilized the parallel computing capabilities of quantum systems to simultaneously compute and evolve multiple quantum states, greatly increasing the computational speed. At the same time, by monitoring and correcting quantum errors, they ensured the reliability of the computational results. By applying holographic technology within the trapped-ion quantum processor, HOLO successfully observed features of quantum chaos and light-cone-related propagation. Quantum chaos is a complex phenomenon in quantum systems, characterized by the high uncertainty and complexity in the evolution of quantum states. Light-cone-related propagation, on the other hand, is an important concept in the field of relativistic quantum information, describing how information propagates within the structure of spacetime. HOLO will continue to focus on improving the performance and stability of quantum bits, reducing noise levels, and increasing the number of quantum bits. By integrating advanced semiconductor technologies and nanotechnology, they aim to develop higher-performance quantum processors. At the same time, they will explore new approaches for realizing quantum bits, such as superconducting qubits, photonic qubits, and others, providing more options for the development of quantum computing. About MicroCloud Hologram Inc. MicroCloud is committed to providing leading holographic technology services to its customers worldwide. MicroCloud's holographic technology services include high-precision holographic light detection and ranging ("LiDAR") solutions, based on holographic technology, exclusive holographic LiDAR point cloud algorithms architecture design, breakthrough technical holographic imaging solutions, holographic LiDAR sensor chip design and holographic vehicle intelligent vision technology to service customers that provide reliable holographic advanced driver assistance systems ("ADAS"). MicroCloud also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's holographic digital twin technology resource library captures shapes and objects in 3D holographic form by utilizing a combination of MicroCloud's holographic digital twin software, digital content, spatial data-driven data science, holographic digital cloud algorithm, and holographic 3D capture technology. For more information, please visit http://ir.mcholo.com/ Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission ("SEC"), including the Company's most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonOpticks will supply Biognosys with custom chromatography columns to support the standardisation of its research services platforms and enable deeper, reproducible proteome profiling. Following extensive consultation with the Biognosys team, IonOpticks has developed a custom chromatography column, which is tailored to Biognosys' needs and is available exclusively for use in their TrueDiscovery®, TrueSignature®, and TrueTarget® contract research services. Consistent with IonOpticks' dedication to high-quality, tailored solutions, the custom column integrates seamlessly into Biognosys' workflows, addressing the company's unwavering criteria for chromatography that maximises sensitivity, depth of coverage and reproducibility in the context of their broader platform. "Collaborating with the world-class team at Biognosys has been an incredibly rewarding experience. Developing a column that stands up to their rigorous performance and quality standards has been an exciting project, aligning well with our broader ambition to continue delivering the best performing columns to meet the expanding needs of the market," says Xavier Perronnet, CEO of IonOpticks. "This partnership is consistent with our mission to work with the best, to develop columns that enable users to push the boundaries of proteomics research, whilst making LC-MS workflows for proteomics more accessible. Biognosys' services are outstanding, and their offerings are extremely valuable to a diverse client base. We're delighted to be contributing our expertise in chromatography to their overall offering," Perronnet continues. "At Biognosys, our priority is to provide the best research services available to a broad array of biotech and pharma customers, requiring scrutiny of every aspect of our platforms to ensure they operate at their peak. Chromatographic performance, the separation of biological analytes prior to detection, is a critical factor for the success of LC-MS workflows and directly impacts discovery outcomes. We were keen to collaborate with the IonOpticks team to develop a chromatography column specifically tailored to our specific requirements, and they delivered," says Lukas Reiter, Ph.D., Chief Technology Officer at Biognosys. IonOpticks and Biognosys are proud to collaborate and set new benchmarks in LC-MS-based research, reaffirming their commitment to delivering high-performance solutions that drive innovation and shape the future of proteomics. --- ENDS --- About IonOpticks IonOpticks produces high-performance chromatography solutions for the global research community enhancing mass spectrometry (LC-MS) and high-end proteomics research. Their solutions enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples. These advancements are valuable for a broad range of applications within the field of biological and medical research including drug discovery, phosphoproteomics and shotgun proteomics. https://ionopticks.com/ About Biognosys At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
A12 藝術空間
Nanotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
